Cantor Fitzgerald resumed coverage on ProQR Therapeutics with a new price target

4/29/25 8:11:53 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Cantor Fitzgerald resumed coverage of ProQR Therapeutics with a rating of Overweight and set a new price target of $8.00

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$PRQR

Date	Price Target	Rating	Analyst
4/29/2025	$5.00	Outperform	Evercore ISI
4/29/2025	$8.00	Overweight	Cantor Fitzgerald
3/10/2025	$4.00	Neutral → Buy	Citigroup
1/10/2025	$15.00	Outperform	Oppenheimer
10/29/2024	$6.00 → $14.00	Outperform → Strong Buy	Raymond James
11/8/2023	$2.00	Neutral → Buy	Chardan Capital Markets
3/30/2023	$1.50 → $5.00	Mkt Perform → Mkt Outperform	JMP Securities
12/22/2022	$0.80 → $5.00	Neutral → Overweight	Cantor Fitzgerald